Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.68 |
| ▸ | CA5A | P35218 | 1/20 | 0.68 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | PLK1 | P53350 | 3/20 | 0.65 |
| ▸ | CA1 | P00915 | 11/20 | 0.64 |
| ▸ | CA9 | Q16790 | 6/20 | 0.64 |
| ▸ | CA4 | P22748 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15325017 | 0.86 | CA1 (0.70) | CA2PTPN7KMT2APLK1CA1 | |
| SCHEMBL29941244 | 0.84 | PTPN7 (0.71) | CA2CA5APTPN7KMT2APLK1 | |
| SCHEMBL3896906 | 0.84 | ALDH1A1 (0.52) | CA2CA5APTPN7KMT2APLK1 | |
| SCHEMBL3896251 | 0.82 | ALDH1A1 (0.50) | CA2CA5APTPN7KMT2APLK1 | |
| SCHEMBL11245631 | 0.82 | TGM2 (0.54) | KMT2APLK1ALDH1A1 | |
| SCHEMBL3896252 | 0.82 | ALDH1A1 (0.50) | CA2CA5APTPN7KMT2APLK1 | |
| SCHEMBL358576 | 0.82 | CA1 (0.80) | CA2PTPN7KMT2ACA1CA9 | |
| SCHEMBL5432082 | 0.81 | PTPN7 (0.72) | CA2PTPN7KMT2APLK1CA1 | |
| SCHEMBL1517568 | 0.80 | KMT2A (0.66) | CA2PTPN7KMT2ACA1CA9 | |
| SCHEMBL725810 | 0.80 | ALDH1A1 (0.75) | KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521287-A | Synthetic preparation method of nicosulfuron original drug | 江苏省激素研究所股份有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-102079732-B | Method for synthesizing 2-amino-4-methylthiazole-5-carboxylate and derivatives thereof | UNIV XI AN JIAOTONG | 2013-03-13 | — | — | CN | claimed |
| US-20240150338-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| EP-4333843-A1 | BITHIAZOL DERATIVES AS INHIBITORS OF LYSYL OXIDASES | University of South Carolina (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240075015-A1 | Inhibitors of Lysyl Oxidases | UNIVERSITY OF SOUTH CAROLINA | 2024-03-07 | — | — | US | disclosed |
| CN-117545480-A | Dithiazole derivatives as inhibitors of lysyl oxidase | 南卡罗来纳大学 | 2024-02-09 | — | — | CN | disclosed |
| CN-117355300-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic diseases | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4277623-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11712437-B2 | Inhibitors of lysyl oxidases | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712437-B2 | Inhibitors of lysyl oxidases | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712437-B2 | Inhibitors of lysyl oxidases | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-08-01 | — | — | US | disclosed |
| EP-1858542-A4 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR PERMEABILITY | JOSLIN DIABETES CENTER INC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080280811-A1 | Carbonic Anhydrase-1 and 2 signal inhibitor; of Vascular Endothelial Growth Factor signal inhibitor; kallikrein, kinin pathway inhibitor; Complement-1 Inhibitor agonist; injection into vitreous or aqueous humor of the eye; candidates by tested for significant difference in level of protein, mRNA | JOSLIN DIABETES CENTER | 2008-11-13 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1858542-A2 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR PERMEABILITY | Joslin Diabetes Center, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006091459-A2 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR PERMEABILITY | JOSLIN DIABETES CENTER, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1421935-A1 | Thiourea carbonic anhydrase inhibitors and their use in treatment of glaucoma | Casini, Angela (IT) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240075015-A1 | Inhibitors of Lysyl Oxidases | LOXL1, LOXL2, LOXL4 | CA2 4497/4885CA5A 3713/4885PTPN7 2255/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | CA2 4115/4885CA5A 3606/4885PTPN7 675/4885 |
| US-11712437-B2 | Inhibitors of lysyl oxidases | LOXL1, LOXL2, LOXL4 | CA2 4472/4885CA5A 3716/4885PTPN7 2432/4885 |
| US-20240150338-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | OAT, NLN, ABAT | CA2 4322/4885CA5A 447/4885PTPN7 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.